Research ExplorerPublicationsCorrelation between DNA damage responses of skin to a test d...

Correlation between DNA damage responses of skin to a test dose of radiation and late adverse effects of earlier breast radiotherapy

Standard

Correlation between DNA damage responses of skin to a test dose of radiation and late adverse effects of earlier breast radiotherapy. / Somaiah, Navita; Chua, Melvin L K; Bourne, Sara; Daley, Frances; A' Hern, Roger; Nuta, Otilia; Gothard, Lone; Boyle, Sue; Herskind, Carsten; Pearson, Ann; Warrington, Jim; Helyer, Sarah; Owen, Roger; Rothkamm, Kai; Yarnold, John.

In: RADIOTHER ONCOL, Vol. 119, No. 2, 05.2016, p. 244-9.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Somaiah, N, Chua, MLK, Bourne, S, Daley, F, A' Hern, R, Nuta, O, Gothard, L, Boyle, S, Herskind, C, Pearson, A, Warrington, J, Helyer, S, Owen, R, Rothkamm, K & Yarnold, J 2016, 'Correlation between DNA damage responses of skin to a test dose of radiation and late adverse effects of earlier breast radiotherapy', RADIOTHER ONCOL, vol. 119, no. 2, pp. 244-9. https://doi.org/10.1016/j.radonc.2016.04.012

APA

Somaiah, N., Chua, M. L. K., Bourne, S., Daley, F., A' Hern, R., Nuta, O., Gothard, L., Boyle, S., Herskind, C., Pearson, A., Warrington, J., Helyer, S., Owen, R., Rothkamm, K., & Yarnold, J. (2016). Correlation between DNA damage responses of skin to a test dose of radiation and late adverse effects of earlier breast radiotherapy. RADIOTHER ONCOL, 119(2), 244-9. https://doi.org/10.1016/j.radonc.2016.04.012

Vancouver

Somaiah N, Chua MLK, Bourne S, Daley F, A' Hern R, Nuta O et al. Correlation between DNA damage responses of skin to a test dose of radiation and late adverse effects of earlier breast radiotherapy. RADIOTHER ONCOL. 2016 May;119(2):244-9. https://doi.org/10.1016/j.radonc.2016.04.012

Bibtex

@article{800e677515534b66bf0e34d22a6ff42b,
title = "Correlation between DNA damage responses of skin to a test dose of radiation and late adverse effects of earlier breast radiotherapy",
abstract = "AIM: To correlate residual double strand breaks (DSB) 24h after 4Gy test doses to skin in vivo and to lymphocytes in vitro with adverse effects of earlier breast radiotherapy (RT).PATIENTS AND METHODS: Patients given whole breast RT ⩾5years earlier were identified on the basis of moderate/marked or minimal/no adverse effects despite the absence ('RT-Sensitive', RT-S) or presence ('RT-Resistant', RT-R) of variables predisposing to late adverse effects. Residual DSB were quantified in skin 24h after a 4Gy test dose in 20 RT-S and 15 RT-R patients. Residual DSB were quantified in lymphocytes irradiated with 4Gy in vitro in 30/35 patients.RESULTS: Mean foci per dermal fibroblast were 3.29 (RT-S) vs 2.80 (RT-R) (p=0.137); 3.28 (RT-S) vs 2.60 (RT-R) in endothelium (p=0.158); 2.50 (RT-S) vs 2.41 (RT-R) in suprabasal keratinocytes (p=0.633); 2.70 (RT-S) vs 2.35 (RT-R) in basal epidermis (p=0.419); 12.1 (RT-S) vs 10.3 (RT-R) in lymphocytes (p=0.0052).CONCLUSIONS: Residual DSB in skin following a 4Gy dose were not significantly associated with risk of late adverse effects of breast radiotherapy, although exploratory analyses suggested an association in severely affected individuals. By contrast, a significant association was detected based on the in vitro response of lymphocytes.",
author = "Navita Somaiah and Chua, {Melvin L K} and Sara Bourne and Frances Daley and {A' Hern}, Roger and Otilia Nuta and Lone Gothard and Sue Boyle and Carsten Herskind and Ann Pearson and Jim Warrington and Sarah Helyer and Roger Owen and Kai Rothkamm and John Yarnold",
note = "Copyright {\textcopyright} 2016 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.",
year = "2016",
month = may,
doi = "10.1016/j.radonc.2016.04.012",
language = "English",
volume = "119",
pages = "244--9",
journal = "RADIOTHER ONCOL",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - Correlation between DNA damage responses of skin to a test dose of radiation and late adverse effects of earlier breast radiotherapy

AU - Somaiah, Navita

AU - Chua, Melvin L K

AU - Bourne, Sara

AU - Daley, Frances

AU - A' Hern, Roger

AU - Nuta, Otilia

AU - Gothard, Lone

AU - Boyle, Sue

AU - Herskind, Carsten

AU - Pearson, Ann

AU - Warrington, Jim

AU - Helyer, Sarah

AU - Owen, Roger

AU - Rothkamm, Kai

AU - Yarnold, John

N1 - Copyright © 2016 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.

PY - 2016/5

Y1 - 2016/5

N2 - AIM: To correlate residual double strand breaks (DSB) 24h after 4Gy test doses to skin in vivo and to lymphocytes in vitro with adverse effects of earlier breast radiotherapy (RT).PATIENTS AND METHODS: Patients given whole breast RT ⩾5years earlier were identified on the basis of moderate/marked or minimal/no adverse effects despite the absence ('RT-Sensitive', RT-S) or presence ('RT-Resistant', RT-R) of variables predisposing to late adverse effects. Residual DSB were quantified in skin 24h after a 4Gy test dose in 20 RT-S and 15 RT-R patients. Residual DSB were quantified in lymphocytes irradiated with 4Gy in vitro in 30/35 patients.RESULTS: Mean foci per dermal fibroblast were 3.29 (RT-S) vs 2.80 (RT-R) (p=0.137); 3.28 (RT-S) vs 2.60 (RT-R) in endothelium (p=0.158); 2.50 (RT-S) vs 2.41 (RT-R) in suprabasal keratinocytes (p=0.633); 2.70 (RT-S) vs 2.35 (RT-R) in basal epidermis (p=0.419); 12.1 (RT-S) vs 10.3 (RT-R) in lymphocytes (p=0.0052).CONCLUSIONS: Residual DSB in skin following a 4Gy dose were not significantly associated with risk of late adverse effects of breast radiotherapy, although exploratory analyses suggested an association in severely affected individuals. By contrast, a significant association was detected based on the in vitro response of lymphocytes.

AB - AIM: To correlate residual double strand breaks (DSB) 24h after 4Gy test doses to skin in vivo and to lymphocytes in vitro with adverse effects of earlier breast radiotherapy (RT).PATIENTS AND METHODS: Patients given whole breast RT ⩾5years earlier were identified on the basis of moderate/marked or minimal/no adverse effects despite the absence ('RT-Sensitive', RT-S) or presence ('RT-Resistant', RT-R) of variables predisposing to late adverse effects. Residual DSB were quantified in skin 24h after a 4Gy test dose in 20 RT-S and 15 RT-R patients. Residual DSB were quantified in lymphocytes irradiated with 4Gy in vitro in 30/35 patients.RESULTS: Mean foci per dermal fibroblast were 3.29 (RT-S) vs 2.80 (RT-R) (p=0.137); 3.28 (RT-S) vs 2.60 (RT-R) in endothelium (p=0.158); 2.50 (RT-S) vs 2.41 (RT-R) in suprabasal keratinocytes (p=0.633); 2.70 (RT-S) vs 2.35 (RT-R) in basal epidermis (p=0.419); 12.1 (RT-S) vs 10.3 (RT-R) in lymphocytes (p=0.0052).CONCLUSIONS: Residual DSB in skin following a 4Gy dose were not significantly associated with risk of late adverse effects of breast radiotherapy, although exploratory analyses suggested an association in severely affected individuals. By contrast, a significant association was detected based on the in vitro response of lymphocytes.

U2 - 10.1016/j.radonc.2016.04.012

DO - 10.1016/j.radonc.2016.04.012

M3 - SCORING: Journal article

C2 - 27106550

VL - 119

SP - 244

EP - 249

JO - RADIOTHER ONCOL

JF - RADIOTHER ONCOL

SN - 0167-8140

IS - 2

ER -